MBX Biosciences announced positive top-line Phase II study results for canvuparatide in treating chronic hypoparathyroidism, achieving the trial’s primary endpoint. The drug demonstrated statistically significant efficacy at week 12 with encouraging six-month extension data. MBX plans to initiate a Phase III trial next year, positioning canvuparatide to compete with approved hormonal replacement therapies in this rare endocrine disorder. The hopeful data has propelled MBX’s stock price upward.